Today we announced a collaboration with EPIC to integrate the Galleri multi-cancer early detection (#MCED) test into EPIC’s electronic health record (EHR) platform, supporting broader adoption across the US #HealthSystems.
Read the press release: https://bit.ly/4vmIMjs
Seven in 10 cancer deaths in the US are from cancer types with no recommended screenings, including pancreatic, liver, ovarian, and esophageal cancers.
Multi-cancer early detection (#MCED) testing offers a path to find more cancers, earlier.
Learn more: https://bit.ly/45phhKK
We will announce fourth quarter and full year 2025 financial results on February 19.
Register for the webcast: https://bit.ly/4rZLqcp
Read more: https://bit.ly/3MHOevD
Following the President’s signature, the Nancy Gardner Sewell Medicare MCED Screening Coverage Act is now law, establishing a Medicare benefit category for MCED tests and a path to meaningful coverage once MCED tests are FDA approved.
Learn more: https://bit.ly/45OQPdv
Listen to Dr. Robert Merritt, a thoracic surgeon who helped treat Fire Lieutenant Kevin McFarland’s stage 1 cancer, discuss multi-cancer early detection (MCED) testing and the importance of #EarlyCancerDetection on the latest episode of The Cancer SIGNAL podcast: https://bit.ly/48PiKfd
#MCED
We’re taking the stage at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 a.m. PT. Live and replay webcasts will be available.
Learn more and how to watch: https://bit.ly/455zjkM
#JPMHealth #JPM2026
Kevin McFarland, a lieutenant with his local fire department, took a multi-cancer early detection (MCED) test that led to a stage 1 diagnosis.
Hear how this experience helped renew his appreciation for his health on the latest episode of The Cancer SIGNAL podcast:
#EarlyCancerDetection #MCED
We’re presenting new research at the upcoming #SUO2025 meeting. Our abstract presentation will reveal findings on the non-invasive detection of residual urothelial carcinoma using cell-free DNA methylation in pre-op urine and plasma samples.
Join us: http://bit.ly/4qNzLgT
Early stage pancreatic cancer often goes undetected, resulting in many people being diagnosed after the cancer has advanced.This Pancreatic Cancer Awareness Day, help us spread the word that #EarlyCancerDetection saves lives.
#PancreaticCancerAwareness
Today GRAIL reported third quarter 2025 financial results.
Learn more: https://bit.ly/47RXsfr
Join us next Thursday for GRAIL’s Analyst Day 2025. Register and watch the live webcast here: https://bit.ly/47K19Ue
On the latest episode of The Cancer SIGNAL podcast, host Susanna Quinn is joined by Nima Nabavizadeh, MD, from Oregon Health & Science University, to discuss the groundbreaking PATHFINDER 2 study findings. Listen here: https://bit.ly/48DGcwp
#EarlyCancerDetection #MCED
Today we announced that we have entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents’ fees and other expenses. Learn more: grail.com/press-releas...
70% of cancer deaths are from cancers that do not have recommended screening tests. In the PATHFINDER 2 study, presented at #ESMO25, approximately three-quarters of the cancers detected by Galleri do not have standard of care screening options. Learn more: https://bit.ly/4n91cP6
Press following #ESMO25:
Join the Press Briefing II - today, 12:30-13:15 CEST, as Dr. Nima Nabavizadeh discusses “Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended-Use Population: Initial Results from the Registrational PATHFINDER 2 Study.”
Coming up tomorrow at #ESMO25 in Berlin - results from the PATHFINDER 2 study. See our press release for more details: https://bit.ly/4n91cP6
It’s #MensBreastCancerAwareness Week, an ideal time to remind everyone that, while rare, #MenGetBreastCancerToo—and they should see their doctor immediately if they notice any unusual symptoms.
#EarlyDetection can help improve their chances for successful treatment.
#LiverCancer is the fourth most common cause of cancer death worldwide, and hepatocellular carcinoma (HCC), which accounts for nearly 75% of all cases, is often diagnosed in advanced stages. We’re observing #LiverCancerAwarenessMonth by promoting #EarlyDetection.
#OctoberIs4Livers
After 20 years of serving her local police department, Darla took a multi-cancer early detection (MCED) test through her insurance company. Despite having no symptoms, her test detected a cancer signal, giving her the chance to take swift action and become cancer free today. https://bit.ly/47aCE3o
How do we bring multi-cancer early detection (MCED) into everyday clinical practice? With more than 35,000 participants, PATHFINDER 2 is the largest U.S. interventional MCED study to date. Ahead of #ESMO25, our president, Dr. Josh Ofman, shares what these data mean: https://bit.ly/46EECck
For #BreastCancerAwarenessMonth, we’re calling out the importance of #EarlyDetection—especially if you’re at risk for the BRCA gene mutation. Learn more by listening to The Cancer SIGNAL: https://bit.ly/4pTkTxc
Celebrate #InternationalPodcastDay by giving The Cancer SIGNAL a listen. On this podcast, we dive into the stories behind multi-cancer early detection (MCED)—from patients to doctors, advocates to researchers, and more. Tune in today: https://bit.ly/47oQpMD
#PodcastCommunity #EarlyCancerDetection
#GynecologicCancerAwarenessMonth serves as a reminder of the importance of routine screenings for detecting cervical cancer early and improving prognosis and treatment success.
#GCAM #PreventCervicalCancer
Tad Carper, a @dallas--cowboys.bsky.social exec, took a multi-cancer early detection (MCED) test—which led to an unexpected journey. Hear how early detection shaped his story on the latest episode of The Cancer SIGNAL podcast:
Apple Podcasts: https://apple.co/4mI2WPm
We’re presenting new data from our PATHFINDER 2 study at the European Society for Medical Oncology 2025 Congress. We are also pleased to be sharing results from our SYMPLIFY and REFLECTION studies at the 2025 Early Detection of Cancer Conference. Read more: https://bit.ly/4nc39Lu #ESMO25
You can observe #WorldLymphomaAwarenessDay by putting your health first and paying attention to unusual symptoms—especially if you’re at high risk for lymphoma—as well as getting regular checkups. Remember that early detection can help ensure more treatment options.
#WLAD
A few compelling numbers in time for Ovarian Cancer Awareness Month: Stage I can be cured in up to 90% of cases, and stage II has a 5-year survival rate of 70%. Yet only 20% are diagnosed at stage I or II, underscoring the need to raise awareness of early detection.
#OvarianCancer #OCAM
Were you aware that while the overall cancer death rate decreased by 34% from 1991 to 2022, the leukemia rate has increased? In observance of Blood Cancer Awareness Month, we’re highlighting the importance of early detection.
#BloodCancerAwareness #Leukemia
Today GRAIL reported second quarter 2025 financial results.
Learn more: grail.com/press-releas...
July is Sarcoma Awareness Month—a time to raise awareness about rare cancers and the importance of early detection. Cancer screenings and a knowledge of symptoms can lead to earlier diagnoses and better treatment outcomes. #SarcomaAwareness #EarlyCancerDetection
